This article has been updated with comments from Illumina.
By a GenomeWeb staff reporter
In its suit, filed last August, LadaTech claimed that Illumina's Genome Analyzer and related products and services infringe a DNA amplification patent it holds.
LadaTech initially filed the suit in August, and said that Illumina refused to enter into a license agreement for the patent.
The suit claims that Illumina's Genome Analyzer and related products and services infringe a patent originally issued to Genelabs and now held by a firm called LadaTech.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.